VA-INTELSAT
7.11.2022 20:01:42 CET | Business Wire | Press release
Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks and leading provider of inflight connectivity (IFC), today announced that scale-up manufacturer SWISSto12 will produce the Intelsat 45 satellite (IS-45). With the order, Intelsat becomes the first commercial customer for the innovative HummingSat geostationary (GEO) telecommunications product.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221107005851/en/
Made with additive manufactured products, HummingSat complements much larger legacy spacecraft, boosting and expanding capacity where needed (Photo: Business Wire)
Scheduled for launch in 2025, Intelsat 45 will provide Ku-band fixed-satellite services enabling Intelsat to provide specialized and efficient service to Media and Network customers.
“The SWISSto12 product brings two innovations to meet our business needs,” said Jean-Luc Froeliger, SVP of Space Systems, Intelsat. “The small size addresses a gap in our fleet strategy, enabling us to be increasingly more targeted to meet specific customer requirements. In addition, the additive-manufacturing process used for this spacecraft is paving the way for faster satellite build cycles in the future. We are confident in the HummingSat technology and want to support the success of new players in the field of commercial communication satellites.”
HummingSats are just over one cubic meter in volume, one-tenth the size of conventional satellites placed in geostationary orbit. SWISSto12 is developing the satellites in collaboration with the European Space Agency (ESA) through its public-private-partnership program. Each HummingSat is designed to launch as a rideshare mission on a rocket carrying one or more large spacecraft to GEO transfer orbit. The new satellite product line recently passed its system requirements review, assessed by a panel of ESA experts.
Dr. Emile de Rijk, SWISSto12 founder and CEO: “The award of the IS-45 program by Intelsat is a landmark moment for SWISSto12. We are humbled to embark on this journey with Intelsat, who are the foundational architects of satellite communications. It is unprecedented for a specialist high growth scale-up to secure a contract of this depth with a leading telecommunications operator. It provides a solid start to our HummingSat product line to open a new chapter in the satellite communications industry.”
About Intelsat
As the foundational architects of satellite technology, Intelsat operates the world’s most trusted satellite telecom network. We apply our unparalleled expertise and global scale to connect people, businesses, and communities, no matter how difficult the challenge. Intelsat is building the future of global communications with the world’s first hybrid, multi-orbit, software-defined 5G network designed for simple, seamless, and secure coverage precisely when and where our customers most need it. Follow the leader in global connectivity and “Imagine Here,” with us, at Intelsat.com.
About Swissto12
SWISSto12 is a leading manufacturer of advanced satellite payloads and systems, including the HummingSat: a small yet powerful geostationary telecommunications satellite. The company’s satellites and payloads benefit from unique and patented 3D printing technologies and associated Radio Frequency (RF) product designs that deliver lightweight, compact, highly performing, and competitive RF functionality.
Besides its space portfolio, the company is also active in telecommunications, surveillance and radar applications for the aeronautic industry. SWISSto12 has developed commercially with success in Europe, the USA and Israel and is the fastest growing Swiss aerospace company. SWISSto12 spun off in 2011 from the Swiss Federal Institute of Technology in Lausanne (EPFL), is privately owned and backed by prominent Swiss and European Investors. Learn more about us: www.swissto12.com
Follow Us on Social Media:
Twitter | LinkedIn | Facebook | Instagram | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005851/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom